References in periodicals archive ?
Headquarters: Tokyo, President: Masuji Sugata, "Toyama Chemical") announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of the antirheumatic agent iguratimod (Eisai brand name: Careram, Toyama Chemical brand name: KOLBET) has been lifted.
It would be prudent to monitor for hematologic toxicity when switching from Leflunomide to another antirheumatic agent with a known potential for hematologic suppression
The ninth member of this group, rituximab (Rituxan), is also used as an antirheumatic agent.
It is a slow acting antirheumatic agent which, if not taken as prescribed, can be toxic and is contraindicated in patients with severe renal, hepatic disorders, alcoholism, bone marrow depression, blood dyscrasias, peptic ulcer, ulcerative colitis and pregnancy (MIMS 2003).
Pfizer stated that Swissmedic, the Swiss agency for therapeutic products, approved tofacitinib as monotherapy or in combination with a disease modifying non-biologic antirheumatic agent, including methotrexate (MTX), in adult patients with moderate-to-severe active RA, who have had an inadequate response or intolerance to MTX.
Last year Boehringer Ingelheim launched a number of new products which achieved rapid success, including the antirheumatic agent MOBIC(R), the anti- AIDS drug VIRAMUNE(R) and ALNA(R), a product to treat benign prostatic hyperplasia, ATROVENT(R), a respiratory drug for the treatment of chronic obstructive bronchitis was the first product in the history of the company to achieve sales in excess of 1 billion marks (1.
This year will see the introduction of an antirheumatic agent, Mobic(R),
Among those are antirheumatic agents such as anti-TNF biologics (3) and methotrexate.
Purpose of this contract is to obtain anti-inflammatory and antirheumatic agents (M01) and opioids (N02A) of salicylic acid and its derivatives (N02BA) and aniline (N02BE).
Conventional, small molecule, disease-modifying antirheumatic agents (DMARDs) remain the mainstay of early-line treatment, but patients who fail such agents, patients with severe disease, or patients in whom conventional DMARDs are contraindicated are treated with biological DMARDs.
Over the forecast period, the GI market's growth will be determined by the growth of the immunosuppressants and antirheumatic agents.
Discover which autoimmune drug classes will provide the greatest franchise growth potential and identify the growth drivers of major treatment classes including immunosuppressants, antirheumatic agents, COX-II inhibitors, NSAIDs and corticosteroids.